Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04771-y ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Masaya Tachibana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan. masaya.tachibana@daiichisankyo.com. Hauptthemen laut MEDLINE: Blood Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: Valemetostat tosylate (valemetostat) is an oral, selective, dual inhibitor of enhancer of zeste homolog (EZH)2 and EZH1. This article reports findings on the mass balance and pharmacokinetics of valemetostat in a phase I study; valemetostat metabolite identification in plasma, urine, and fecal samples; and plasma-protein-binding of valemetostat in vitro. METHODS: Eight healthy participants received a single 200-mg oral dose of [14C]-valemetostat under fasting conditions. Blood, urine, and feces samples were collected to determine total radioactivity and/or unchanged valemetostat, and for metabolite identification. The binding of valemetostat 600-10,000 ng/mL to plasma, 4% human serum albumin (HSA), and 0.1% alpha-1-acid glycoprotein (AAG) was assessed in vitro. RESULTS: Mean cumulative recovery of administered radioactivity was 95.3% by 360 h post-dose, with a mean recovery of 15.6% in urine and 79.8% in feces. Valemetostat accounted for the most radioactivity in the excreta, at 10% and 64.9% of the administered dose in the urine and feces, respectively. CALZ-1809a was the most abundant metabolite, present in all biological samples, and accounted for 5.6% of total radioactivity in the feces. Valemetostat was minimally associated with red blood cells, with a blood-to-plasma total radioactivity ratio of 0.54. In vitro, valemetostat was highly plasma-bound (> 94%) at clinically relevant concentrations, with a higher affinity to AAG than to HSA. CONCLUSION: Valemetostat was rapidly absorbed into the systemic circulation, mainly excreted via the biliary/fecal route, primarily metabolized by CYP3A enzymes to CALZ-1809a, and highly bound to plasma proteins, with a greater affinity to AAG than HSA in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan. masaya.tachibana@daiichisankyo.com.
- Covance Clinical Research Unit, Madison, WI, USA.
- Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
- Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
- Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Zitieren
APA
Tachibana, M., Siebers, N., Craveiro, T. V., Kazui, M., Ikeda, T., Shimizu, T., Inaba, S., & Abutarif, M. A. (2025). Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04771-y
Vancouver
Tachibana M, Siebers N, Craveiro TV, Kazui M, Ikeda T, Shimizu T, et al. Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04771-y
BibTeX
@article{Tachibana2025,
author = {Tachibana, Masaya and Siebers, Nicholas and Craveiro, Thuy Vu and Kazui, Miho and Ikeda, Tomoko and Shimizu, Takako and Inaba, Shinichi and Abutarif, Malaz A},
title = {Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04771-y}
}
EUVIMED